Physician profile
Barsha Sharma
NPI 1528652724
$2,141.11
in general payments reported to CMS, 2019-2025
24 companies · $835 in 2025
The $835 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $46.49 · 2023: $559 · 2024: $701 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.54 | 2022-2025 | |
| Lilly USA, LLC | $325.62 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $219.99 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $204.81 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.95 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $145.19 | 2023-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $112.58 | 2022-2024 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $73.71 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Dexcom, INC. | $61.65 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $52.50 | 2024-2025 | |
| Pfizer INC. | $47.75 | 2024-2025 | |
| Intuity Medical INC | $36.01 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Exact Sciences Corporation | $31.64 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Neurocrine Biosciences, INC. | $26.88 | 2025 | |
| Xeris Pharmaceuticals, INC. | $23.17 | 2025 | Recorlev |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $21.48 | 2025 | |
| Cranial Technologies, INC | $20.33 | 2024 | Doc Band |
| Mannkind Corporation | $19.18 | 2023 | Afrezza |
| Seqirus USA INC | $18.78 | 2025 | Fluad, Flucelvax |
| Kowa Pharmaceuticals America, INC. | $16.84 | 2025 | Zoryve |
| Echosens North America, INC. | $15.51 | 2025 | Fibroscan |
| Alnylam Pharmaceuticals INC. | $15.43 | 2025 | Givlaari |
| Dynavax Technologies Corporation | $15.02 | 2025 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.55 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barsha Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.